New combo therapy aims to boost liver cancer surgery success
Disease control
Recruiting now
This early-phase trial is testing whether combining two immunotherapy drugs (durvalumab and tremelimumab) with targeted radiation (yttrium-90 microspheres) can safely shrink liver tumors before surgery. About 20 people with resectable hepatocellular carcinoma will receive the com…
Phase: PHASE1 • Sponsor: Jiping Wang, MD, PhD • Aim: Disease control
Last updated Jun 26, 2026 12:44 UTC